Safety Study of Tivanisiran to Treat Dry Eye

PHASE3CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

October 11, 2023

Study Completion Date

October 11, 2023

Conditions
Dry Eye Disease
Interventions
DRUG

Tivanisiran sodium ophthalmic solution

1 drop in the affected eye(s) once daily

DRUG

Vehicle ophthalmic solution

1 drop in the affected eye(s) once daily

Trial Locations (25)

14618

Sylentis Investigative Site, Rochester

16066

Sylentis Investigative Site, Cranberry Township

27529

Sylentis Investigative Site, Garner

28803

Sylentis Investigative Site, Asheville

30260

Sylentis Investigative Site, Morrow

32256

FYDES Investigative Site, Jacksonville

33484

FYDES Investigative Site, Delray Beach

33773

Sylentis Investigative Site, Largo

38119

Sylentis Investigative Site, Memphis

48026

Sylentis Investigative Site, Fraser

57701

Sylentis Investigative Site, Rapid City

63090

Sylentis Investigative Site, Washington

63131

FYDES Investigative Site, St Louis

64111

Sylentis Investigative Site, Kansas City

78215

Sylentis Investigative Site, San Antonio

78230

Sylentis Investigative Site, San Antonio

78731

Sylentis Investigative Site, Austin

79902

FYDES Investigative Site, El Paso

85021

Sylentis Investigative Site, Chandler

85032

Sylentis Investigative Site, Phoenix

Sylentis Investigative Site, Los Angeles

91204

FYDES Investigative Site, Glendale

92545

Sylentis Investigative Site, Hemet

92562

Sylentis Investigative Site, Murrieta

92663

Sylentis Investigative Site, Newport Beach

All Listed Sponsors
lead

Sylentis, S.A.

INDUSTRY